ArticleJournal of cancer research and clinical oncology2026
Efficacy and safety of transarterial chemoembolization (TACE) with tislelizumab and tyrosine kinase inhibitors versus TACE for intermediate and advanced HCC.
Article in Journal of cancer research and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsTransarterial chemoembolization (TACE) combined with targeted therapy and immunotherapy is a promising approach for intermediate and advanced hepatocellular carcinoma (HCC). This study aimed to compare the efficacy and safety of TACE plus tislelizumab and tyrosine kinase inhibitors (TKIs) versus TACE alone.
methodsThis retrospective study analyzed patients with intermediate and advanced HCC treated from February 2018 to September 2023. Patients were divided into two groups: the combination therapy group (TACE plus tislelizumab and TKIs) and the monotherapy group (TACE alone). The primary endpoint was progression-free survival PFS), and secondary endpoints included objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety. Cox regression, sensitivity analysis, Kaplan-Meier survival curves, and restricted mean survival time (RMST) analysis were performed to assess the robustness of the PFS benefit.
resultsA total of 62 patients were included (30 in the combination group, 32 in the monotherapy group), with balanced baseline characteristics. After a median follow-up of 33.3 months, median PFS was 11.7 months in the combination group and 3.8 months in the monotherapy group (hazard ratio [HR], 0.43; 95% confidence interval [CI], 0.24-0.77; P = 0.0034). This benefit persisted after multivariable adjustment (adjusted HR, 0.28; 95% CI 0.14-0.57; P < 0.001) and was confirmed by sensitivity and RMST analyses at 12, 24, 36, and 48 months (all P < 0.01). The combination group also showed favorable outcomes in secondary endpoints including ORR, DCR, and OS rates. Four patients (13.3%) in the combination group underwent downstaging to curative treatment, with PFS ranging from 14.8 to 49.2 months. Grade ≥ 3 adverse events occurred in 10.0% of the combination group and in none of the monotherapy group, with no treatment-related deaths.
conclusionsTACE combined with tislelizumab and TKIs significantly improved PFS compared with TACE alone, with a manageable safety profile, in patients with intermediate and advanced HCC. This regimen may offer a potential conversion option for selected patients in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.